| Popis: |
Thang Thanh Phan1,2, Ha The Vy3, Toan Trong Ho2, Vinh Thanh Tran2, Tung Thanh Tran3, Suong Phuoc Pho1, Tuyen Thi Bich Pham2, Thao Thi Le2, Son Truong Nguyen4,5 1Biomolecular & Genetic Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 2Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 3Department of Hematology, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 4Department of General Director, Cho Ray Hospital, Ho Chi Minh City 700000, Vietnam; 5Department of the Vice Minister, Ministry of Health, Hanoi City 100000, VietnamCorrespondence: Son Truong NguyenDepartment of the Vice Minister, Ministry of Health, 138A Giang Vo Street, Ba Dinh District, Hanoi City 100000, VietnamTel +84 246 273 2273Fax +84 243 846 4051Email truongson_cr@yahoo.com.vnPurpose: To investigate and evaluate the role of nucleated red blood cells (NRBCs) and other markers in predicting remission failure in chronic myeloid leukemia (CML) patients treated with imatinib.Methods: Seventy-one CML patients with BCR-ABL(+) in bone marrow cells were selected for this study. Molecular response evaluations were done every three months according to the recommendations of European LeukemiaNet (ELN). Patients were defined as remission failure if BCR-ABL transcripts >10% after 6months (T6), >1% after 12months (T12), and >0.1% after 18 (T18) months of treatment. The logistic regression was used to determine the optimal cut-off point of each marker and test the association of marker level with remission failure.Results: The median NRBC, white blood cells, blast cells, basophils, and platelets were declined parallel with the decreases of BCR-ABL transcripts in bone marrow cells after 6months of treatment (P |
